SG11201806153QA - 2-oxindole compounds - Google Patents
2-oxindole compoundsInfo
- Publication number
- SG11201806153QA SG11201806153QA SG11201806153QA SG11201806153QA SG11201806153QA SG 11201806153Q A SG11201806153Q A SG 11201806153QA SG 11201806153Q A SG11201806153Q A SG 11201806153QA SG 11201806153Q A SG11201806153Q A SG 11201806153QA SG 11201806153Q A SG11201806153Q A SG 11201806153QA
- Authority
- SG
- Singapore
- Prior art keywords
- avenue
- international
- pct
- mountain view
- drive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662280969P | 2016-01-20 | 2016-01-20 | |
| PCT/US2017/013899 WO2017127409A1 (en) | 2016-01-20 | 2017-01-18 | 2-oxindole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806153QA true SG11201806153QA (en) | 2018-08-30 |
Family
ID=59314376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806153QA SG11201806153QA (en) | 2016-01-20 | 2017-01-18 | 2-oxindole compounds |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20170204087A1 (sv) |
| EP (1) | EP3405455B1 (sv) |
| JP (1) | JP6898334B6 (sv) |
| KR (1) | KR20180101565A (sv) |
| CN (1) | CN108698991B (sv) |
| AR (1) | AR107398A1 (sv) |
| AU (1) | AU2017209023B2 (sv) |
| BR (1) | BR112018014666B1 (sv) |
| CA (1) | CA3011639A1 (sv) |
| IL (1) | IL260635B (sv) |
| MA (1) | MA43799A (sv) |
| MX (1) | MX2018008895A (sv) |
| NZ (1) | NZ744468A (sv) |
| RU (1) | RU2743747C2 (sv) |
| SG (1) | SG11201806153QA (sv) |
| TW (1) | TWI729059B (sv) |
| WO (1) | WO2017127409A1 (sv) |
| ZA (1) | ZA201804966B (sv) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018014666B1 (pt) | 2016-01-20 | 2024-01-02 | Chemocentryx, Inc | Compostos de 2-oxindol, seu uso e composição farmacêutica |
| JP2022539830A (ja) | 2019-07-10 | 2022-09-13 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１阻害剤としてのインダン |
| WO2021079679A1 (ja) * | 2019-10-21 | 2021-04-29 | 信越化学工業株式会社 | 感光性樹脂組成物、感光性ドライフィルム及びパターン形成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| FR2686878B1 (fr) * | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| DE69718968T2 (de) | 1996-01-17 | 2003-10-09 | Taiho Pharmaceutical Co Ltd | 3-(bis-substituierte-phenylmethylen)oxindol-derivate |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| FR2807038B1 (fr) * | 2000-04-03 | 2002-08-16 | Sanofi Synthelabo | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
| US7250442B2 (en) | 2002-03-15 | 2007-07-31 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
| ATE517102T1 (de) * | 2002-11-18 | 2011-08-15 | Chemocentryx Inc | Arylsulfonamide |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| US8466188B2 (en) | 2006-10-12 | 2013-06-18 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| FR2909668B1 (fr) * | 2006-12-12 | 2009-01-23 | Sanofi Aventis Sa | Derives de 5-alkyloxy-indolin-2-one,leur preparation et leurs applications en therapeutique |
| ATE483685T1 (de) * | 2007-02-06 | 2010-10-15 | Novartis Ag | 1-benzensulfonyl-1h-indol-derivate als hemmer der ccr9-aktivität |
| EP2942350A1 (en) * | 2008-10-17 | 2015-11-11 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| WO2011069298A1 (en) * | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Novel cyclopropane indolinone derivatives |
| AU2013225938B2 (en) * | 2012-02-29 | 2017-08-10 | Chemocentryx, Inc. | Pyrazol-1-yl benzene sulfonamides as CCR9 antagonists |
| US9715915B2 (en) | 2014-10-30 | 2017-07-25 | Samsung Electronics Co., Ltd. | Magneto-resistive devices including a free layer having different magnetic properties during operations |
| BR112018014666B1 (pt) | 2016-01-20 | 2024-01-02 | Chemocentryx, Inc | Compostos de 2-oxindol, seu uso e composição farmacêutica |
-
2017
- 2017-01-18 BR BR112018014666-8A patent/BR112018014666B1/pt active IP Right Grant
- 2017-01-18 MA MA043799A patent/MA43799A/fr unknown
- 2017-01-18 WO PCT/US2017/013899 patent/WO2017127409A1/en active Application Filing
- 2017-01-18 US US15/408,896 patent/US20170204087A1/en not_active Abandoned
- 2017-01-18 JP JP2018537816A patent/JP6898334B6/ja active Active
- 2017-01-18 NZ NZ744468A patent/NZ744468A/en unknown
- 2017-01-18 CA CA3011639A patent/CA3011639A1/en active Pending
- 2017-01-18 CN CN201780007677.XA patent/CN108698991B/zh active Active
- 2017-01-18 RU RU2018129849A patent/RU2743747C2/ru active
- 2017-01-18 MX MX2018008895A patent/MX2018008895A/es unknown
- 2017-01-18 KR KR1020187023830A patent/KR20180101565A/ko not_active Application Discontinuation
- 2017-01-18 EP EP17741838.1A patent/EP3405455B1/en active Active
- 2017-01-18 AU AU2017209023A patent/AU2017209023B2/en active Active
- 2017-01-18 TW TW106101711A patent/TWI729059B/zh active
- 2017-01-18 SG SG11201806153QA patent/SG11201806153QA/en unknown
- 2017-01-19 AR ARP170100150A patent/AR107398A1/es unknown
-
2018
- 2018-03-07 US US15/914,900 patent/US10421748B2/en active Active
- 2018-07-17 IL IL260635A patent/IL260635B/en active IP Right Grant
- 2018-07-24 ZA ZA2018/04966A patent/ZA201804966B/en unknown
-
2019
- 2019-07-29 US US16/524,618 patent/US10759789B2/en active Active
-
2020
- 2020-07-17 US US16/932,114 patent/US11434230B2/en active Active
-
2022
- 2022-08-01 US US17/816,614 patent/US20230119895A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201808821WA (en) | Agonistic antibodies that bind human cd40 and uses thereof | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201804134YA (en) | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201804309PA (en) | Antibody molecules to april and uses thereof | |
| SG11201903483VA (en) | Compositions and methods for treating ezh2-mediated cancer | |
| SG11201809688RA (en) | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201804672QA (en) | Systems and methods for production of low oxygen content silicon | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201407793TA (en) | Compounds and compositions for modulating egfr activity | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201804936UA (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201804205UA (en) | Media mixing chamber |